Sanofi (Euronext:SAN; NYSE:SNY) discontinued development of fedratinib (SAR302503), a selective oral Janus kinase-2 (JAK-2) inhibitor that was in Phase III testing for myeloproliferative disorders including primary myelofibrosis (PMF). According to the pharma, FDA had placed a clinical hold on all trials of fedratinib as a result of cases "consistent with Wernicke's encephalopathy" in patients receiving the compound. Sanofi said it determined the safety risk of fedratinib outweighed its benefit. The pharma gained the product through its 2010 acquisition of TargeGen Inc. for $75 million up front and up to $485 million in milestones. 
DRUG DEVELOPMENT DECONSTRUCTOR MANIFESTO: : “Tell me how you read and I'll tell you who you are.” ― Martin Heidegger
Tuesday, November 19, 2013
Targeted failure of the week. Post No 125. Fedratinib (SAR302503)
Sanofi (Euronext:SAN; NYSE:SNY) discontinued development of fedratinib (SAR302503), a selective oral Janus kinase-2 (JAK-2) inhibitor that was in Phase III testing for myeloproliferative disorders including primary myelofibrosis (PMF). According to the pharma, FDA had placed a clinical hold on all trials of fedratinib as a result of cases "consistent with Wernicke's encephalopathy" in patients receiving the compound. Sanofi said it determined the safety risk of fedratinib outweighed its benefit. The pharma gained the product through its 2010 acquisition of TargeGen Inc. for $75 million up front and up to $485 million in milestones. 
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment